This confirms a previous report suggesting that pharmacological inhibition of the hyperactivated eIF4E, which is induced by FMRP defects, has the potential to ameliorate the FXS-like phenotypes [25]. The gene discussed is EIF4E; the disease is fragile X syndrome.